Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

Press/Media: Expert Comment › Professional

Period	12-Apr-2025

Media contributions

Title	Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL
Degree of recognition	International
Media name/outlet	OncLive
Media type	Television
Duration/Length/Size	58 seconden
Date	12/04/2025
URL	https://www.onclive.com/view/dr-van-meerten-on-the-optimal-use-of-brexu-cel-in-btk-inhibitor-naive-mcl
Persons	Tom van Meerten